News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS)'s Jakavi Turned Down by National Institute for Clinical Excellence (NICE) for Blood Cancer


2/13/2013 7:24:42 AM

A new drug from Novartis for myelofibrosis, a rare blood cancer, is not worth using on the state health service, Britain's healthcare cost watchdog said on Wednesday. The National Institute for Health and Clinical Excellence (NICE) said it had issued new draft guidance not recommending Jakavi because it could not be considered a cost-effective use of resources. The drug costs 3,600 pounds ($5,600) for a 60-tablet pack, corresponding to an annual cost of approximately 43,200 pounds per patient. Jakavi, which was licensed from Incyte, was given a marketing authorisation in Europe last August.

Read at Reuters
Read at Bloomberg
Read at News Release
Read at News Release
Read at Pharma Times [Free Reg Req'd]


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES